why choose us

First received: April 24, 2023

Clinical Trial: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pneumococcal Vaccines

Study Type: INTERVENTIONAL


Official Title: Randomized, Observer-Blind, Active-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Immunogenicity of 24-Valent PCV (VAX-24) in Infants Given 4 Doses at 2, 4, 6, and 12-15 Mont

Brief Summary: The objective of the study is to evaluate the safety and tolerability of 4 injections of VAX-24 (at 3 dose levels) compared to PCV15 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines.Stage 1 of the study will comprise 3 dose ascending cohorts.Stage 2 of the study will enroll the remainder of the sample size.

Read more